Paris, France, Wednesday, January 15, 2025, 7:30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the publication of outcomes data from five years’ follow-up of patients treated unilaterally with LUMEVOQ
®, the company’s investigational gene therapy for Leber Hereditary Optic Neuropathy (LHON) due to a mutated
ND4 mitochondrial gene. The patients had all participated in the Phase III trials RESCUE and REVERSE and accepted enrolling into the long-term study RESTORE at the end of the RESCUE and REVERSE studies.
The paper, published online by the leading journal
JAMA Ophthalmology in December 2024, found that patients “demonstrated a sustained bilateral improvement in BCVA [Best-Corrected Visual Acuity] and a good safety profile over 5 years after treatment”. The “persistent benefit” continues the durable effect observed at
earlier time points and represents a significant addition to the body of evidence on the benefit-risk ratio of LUMEVOQ
® gene therapy in
ND4 LHON patients.
“
The findings on the persistence of visual improvement show the promise of using LUMEVOQ gene therapy to treat patients with LHON due to the MT-ND4 gene variant,” noted
Prof. Patrick Yu-Wai-Man,
MD, PhD, Professor of Ophthalmology and Honorary Consultant Neuro-ophthalmologist at the University of Cambridge, Moorfields Eye Hospital, and the UCL Institute of Ophthalmology, United Kingdom, lead author and Principal Investigator in the RESCUE, REVERSE and RESTORE studies. “
The results are especially encouraging given the poor visual prognosis of MT-ND4 LHON, which is the most frequent and severe clinical form of this rare mitochondrial genetic disease.”
When RESTORE participants enrolled in the study, 2 years after the one-time injection, they had already experienced clinically meaningful improvement relative to the lowest point (the “nadir”) of their Best-Corrected Visual Acuity (BCVA): +20 ETDRS letters equivalent in their LUMEVOQ
®-treated eyes and +17 ETDRS letters equivalent in their sham-treated eyes. Five years after treatment, the bilateral improvement from nadir was sustained, with LUMEVOQ
®-treated eyes achieving a mean improvement against nadir of +22 letters equivalent and sham-treated eyes demonstrating a mean improvement of +20 letters equivalent.
Table 1. Change in BCVA Vs. Nadir* In LUMEVOQ® Long-Term Follow-Up (RESTORE)
|
2 Years Post-Injection |
5 Years Post-Injection |
| LogMAR
Mean (SD) |
Letters Equivalent** |
LogMAR Mean (SD) |
Letters Equivalent** |
| LUMEVOQ®-treated eyes |
-0.4
(0.4) |
+20
|
-0.4
(0.5) |
+22
|
| Sham-treated eyes |
-0.3
(0.3) |
+17
|
-0.4
(0.4) |
+20
|
SD: Standard Deviation. Imputed data in alignment with the statistical analysis plan. Figures in this table were extracted from eTable 2 of the article. The RESTORE sample consists of the RESCUE and REVERSE participants who accepted to be followed in the long-term follow-up study. *Nadir = worst best-corrected visual acuity recorded from baseline to time point of interest. **Assessments of best-corrected visual acuity (BCVA) were recorded in LogMAR. The change from nadir in LogMAR was converted to “
letters equivalent” improvement by multiplying the LogMAR by -50 (ref. J.T. Holladay,
J Refrac Surgery, 1997;13, 388-391).
Responder analyses at Year 5 indicate that improved BCVA was a benefit for a substantial proportion of the study participants. 66.1% of RESTORE participants achieved clinically meaningful (at least +3 lines’ improvement) from nadir in at least one eye, and the proportion rises to 71.0% if the criterion used is Clinically Relevant Recovery (CRR)
1 against nadir. At the end of the five-year follow-up period, 80.6% of participants had on-chart vision (BCVA ≤ 1.6 LogMAR) in at least one eye.
The impact of such results on patients is demonstrated by increases in the self-reported quality of life (QoL) scores at Year 5 vs. baseline. Clinically significant improvement from baseline was observed in 7 of 10 subscale scores of the NEI VFQ-25 questionnaire used to assess quality of life. The composite score showed a clinically meaningful gain of 7 points from baseline.
Safety findings at 5 years post-injection were consistent with previous readouts, which concluded that LUMEVOQ
® is well-tolerated. The systemic safety was excellent and most ocular events were mild, none were severe or serious, and none led to study discontinuation.
RESTORE is one of the largest long-term follow-up studies for a rare disease treatment, with 62 participants accepting the invitation to enroll. All participants were treated with a single intravitreal injection of LUMEVOQ
® in one eye and with sham injection in the other.
The full article is available online on
this link.
Definition:
- Clinically Relevant Recovery (CRR) corresponds to an improvement of at least 0.2 LogMAR (for on-chart eyes) or a movement from off-chart to on-chart (for off-chart eyes).